Community norms of the Muscle Dysmorphic Disorder Inventory (MDDI) among cisgender sexual minority men and women

Jason M. Nagata  
*University of California, San Francisco*

Emilio J. Compte  
*Universidad Adolfo Ibáñez*

Chloe J. Cattle  
*University of California, San Francisco*

Jason M. Lavender  
*Uniformed Services University of the Health Sciences*

Tiffany A. Brown  
*Department of Psychiatry*

*See next page for additional authors*

Follow this and additional works at: [https://scholarworks.sjsu.edu/faculty_rsca](https://scholarworks.sjsu.edu/faculty_rsca)

**Recommended Citation**

Jason M. Nagata, Emilio J. Compte, Chloe J. Cattle, Jason M. Lavender, Tiffany A. Brown, Stuart B. Murray, Annesa Flentje, Matthew R. Capriotti, Micah E. Lubensky, Juno Obedin-Maliver, and Mitchell R. Lunn. "Community norms of the Muscle Dysmorphic Disorder Inventory (MDDI) among cisgender sexual minority men and women" *BMC Psychiatry* (2021). [https://doi.org/10.1186/s12888-021-03302-2](https://doi.org/10.1186/s12888-021-03302-2)

This Article is brought to you for free and open access by SJSU ScholarWorks. It has been accepted for inclusion in Faculty Research, Scholarly, and Creative Activity by an authorized administrator of SJSU ScholarWorks. For more information, please contact scholarworks@sjsu.edu.
Authors
Jason M. Nagata, Emilio J. Compte, Chloe J. Cattle, Jason M. Lavender, Tiffany A. Brown, Stuart B. Murray, Annessa Flentje, Matthew R. Capriotti, Micah E. Lubensky, Juno Obedin-Maliver, and Mitchell R. Lunn

This article is available at SJSU ScholarWorks: https://scholarworks.sjsu.edu/faculty_rsca/2380
Community norms of the Muscle Dysmorphic Disorder Inventory (MDDI) among cisgender sexual minority men and women

Jason M. Nagata 1*, Emilio J. Compte 2,3, Chloe J. Cattle 1, Jason M. Lavender 4,5, Tiffany A. Brown 6,7, Stuart B. Murray 8, Annesa Flentje 9,10,11, Matthew R. Capriotti 11,12, Micah E. Lubensky 9,11, Juno Obedin-Maliver 11,13,14 and Mitchell R. Lunn 11,14,15

Abstract

Background: Representing the pathological extreme pursuit of muscularity, muscle dysmorphia (MD) is characterized by a pervasive belief or fear around insufficient muscularity and an elevated drive for muscularity. Despite evidence of elevated body image-related concerns among sexual minority populations, little is known about the degree of muscle dysmorphia (MD) symptoms among sexual minorities, particularly based on Muscle Dysmorphic Disorder Inventory (MDDI) scores. The objective of this study was to examine the nature and severity of MD symptoms in cisgender sexual minority men and women and provide community norms of the MDDI for these populations.

Methods: Data from participants in The PRIDE Study, an existing study of health outcomes in sexual and gender minority people from the United States, were examined. Participants included cisgender gay men (N = 1090), cisgender bisexual plus (bisexual, pansexual, and/or polysexual) men (N = 100), cisgender lesbian women (N = 563), and cisgender bisexual plus women (N = 507). We calculated means, standard deviations (SD), and percentiles for the MDDI total and subscale scores for cisgender sexual minority men and women. We compared MDDI scores by sexual orientation using linear regression models, both unadjusted and adjusted for sociodemographics.

Results: Overall, the sample was 85.2% White, 3.0% Asian or Pacific Islander, 2.0% Black, 0.5% Native American, 3.9% multiracial, and 6.6% Hispanic/Latino/a. The mean age was 38.6 (SD = 14.3) and 69.4% had a college degree or higher. Means (SD) for the MDDI total score were 27.4 (7.7) for cisgender gay men, 26.4 (6.4) for cisgender bisexual plus men, 24.3 (6.1) for cisgender lesbian women, and 24.6 (5.5) for cisgender bisexual plus women. There were no significant differences in MDDI scores between cisgender gay and bisexual plus men, or between cisgender lesbian women and bisexual plus women in unadjusted or adjusted models.

Conclusions: These normative data provide insights into the experience of MD symptoms among cisgender sexual minority men and women and can aid researchers and clinicians in the evaluation of MD symptoms and interpretation of MDDI scores in sexual minority populations.

* Correspondence: jason.nagata@ucsf.edu
1Department of Pediatrics, University of California, San Francisco, Box 0110, 550 16th Street, 4th Floor, San Francisco, CA 94158, USA
Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Muscle dysmorphia (MD), currently diagnosed using a specifier for Body Dysmorphic Disorder (BDD) in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5, American Psychiatric Association, 2013), is characterized by the pathological pursuit of muscularity and a preoccupation with one’s body size as not being large enough [1, 2]. The condition is associated with numerous behavioral disturbances, including excessive exercise training, rigid diets, disordered eating patterns, and anabolic steroid use [3–5]. Individuals with MD commonly report that they have little to no control over these behaviors and have been found to exhibit poor insight related to these behaviors [6]. Notably, there is significant comorbidity between MD and various forms of psychopathology, particularly mood and anxiety disorders [6–8], as well as substance use and suicidality [4, 9]. Along with the shame and distress associated with MD, the time-consuming and rigid nature of the common behavioral patterns promotes significant impairments in social and occupational functioning [2, 4]. Cumulatively, these findings emphasize the high degree of distress and impairment than can arise from MD and the importance of characterizing the nature and degree of MD symptoms in at-risk populations.

Although the literature on MD has expanded in recent years, questions still remain regarding how MD symptoms present across various identity dimensions [10]. Specifically, MD was initially characterized in reference to bodybuilding men, and the majority of MD research has utilized small sample sizes of presumably cisgender (i.e., those whose gender identity matches what is commonly associated with the sex assigned to them at birth) heterosexual populations of men [8, 10, 11]. For example, in a recent meta-analysis of 34 studies on MD, only six had samples that included participants who identified as women [12]. Nearly all of these studies neglected to assess or report the sexual orientation of participants, which is particularly problematic given evidence suggesting that gay (versus heterosexual) men are more likely to endorse dissatisfaction with their physical appearance and muscle size/tone [13] and to hold distorted cognitions about the importance of having an “ideal physique” [14, 15]. Preliminary evidence also suggests that both gay (versus heterosexual) men and lesbian (versus heterosexual) women exhibit a greater drive for muscularity [16]. Gay men (presumably cisgender) report being most dissatisfied with their muscularity compared to other body parts, and muscularity is considered important to being perceived as physically attractive [17]. Studies of BDD also have found that sexual minority individuals (presumably cisgender) endorsed a greater number of BDD symptoms than heterosexual individuals [18]. Further, among sexual minority adolescent boys and young men, gay-related rejection sensitivity and sexual orientation concealment were associated with greater BDD symptoms [19]. Notably, there are extremely limited data on MD-related symptoms among individuals with plurisexual identities (i.e., romantic or sexual attraction and/or behavior with members of more than one sex or gender), such as bisexual, pansexual, and polysexual identities, which we refer to as bisexual plus.

With regard to the measures that have been developed to assess and screen for MD, the Muscle Dysmorphic Disorder Inventory (MDDI) [20] has been one of the most widely used. The 13-item questionnaire consists of three subscales focusing on unique components of MD, including drive for size, appearance intolerance, and functional impairment. Functional impairment in particular represents a crucial element of the disorder that certain other measures fail to assess [21]. The MDDI has been psychometrically examined in diverse samples of men—spanning multiple languages, countries, and demographics—with results suggesting that the MDDI scores demonstrate reliability and validity across a variety of populations [5, 9, 22–26]. However, there remains a lack of published normative data for the MDDI, including in at-risk populations, such as cisgender sexual minority people, limiting the interpretability of scores on the measure in certain groups.

In order to address the paucity of MD literature on sexual minorities and to provide insights into the nature and degree of MD symptoms within these populations, the present study examined MDDI norms in community samples of cisgender gay men, cisgender bisexual plus men, cisgender lesbian women, and cisgender bisexual plus women. Further, to characterize differences within the samples of cisgender men and cisgender women reporting different sexual orientations, we conducted both unadjusted and adjusted (for sociodemographic characteristics) comparisons of MDDI mean total and subscale scores in cisgender gay versus cisgender bisexual men, and in cisgender lesbian versus cisgender bisexual women.

Method
Study population
Data in this study were drawn from a subsample of participants from The Population Research in Identity and
Disparities for Equality (PRIDE) Study who completed the 'Eating and Body Image' survey from April 2018 to August 2018. Of the 10,665 participants in The PRIDE Study at that time, 4285 completed the 'Eating and Body Image' survey. The PRIDE Study is a large-scale, national (United States), and longitudinal cohort study of sexual and gender minority adults. Specific inclusion criteria were: identification as a sexual and/or gender minority person, living in the United States or its territories, age ≥18 years, and ability to read and respond to a questionnaire written in English. Participants were recruited through PRIDEnet (a national network of organizations and individuals to engage sexual and gender minority communities), digital communications (e.g., blog posts, newsletters), distribution of The PRIDE Study-branded promotional items, outreach at conferences and events, social media advertising, and word-of-mouth. Data were collected on a cloud-based, web-responsive, and secure platform accessible from any smartphone, tablet, or computer. Additional details about The PRIDE Study research platform, recruitment, and design are reported elsewhere [27, 28].

For this study, we included cisgender gay men, cisgender bisexual plus men, cisgender lesbian women, and cisgender bisexual plus women. Participants were asked about the sex assigned to them at birth (“What sex were you assigned at birth on your original birth certificate?”), their current gender identity (with the option to indicate more than one), and their sexual orientation (with the option to indicate more than one). Additional file 1 describes the classification rules that were applied to form the final samples. Of the 4285 participants who completed the ‘Eating and Body Image’ survey, the final sample included participants (n = 2260) who were classified as cisgender gay men (N = 1090), cisgender bisexual plus men (N = 100), cisgender lesbian women (N = 563), and cisgender bisexual plus women (N = 507). No compensation was given for survey completion. This study was approved by the University of California, San Francisco and Stanford University Institutional Review Boards, as well as The PRIDE Study’s Research Advisory Committee and Participant Advisory Committee. All study procedures and methods were carried out in accordance with relevant guidelines and regulations.

**Measures**

**Sociodemographic questionnaire**

Sociodemographic information including age, race/ethnicity, country of birth, and education level was self-reported. Body mass index (BMI) was calculated from self-reported weight and height [weight (kg)/height (m)^2]. Questions also assessed participant history regarding diagnosed BDD and MD. Specifically, participants were asked, “Has a mental health professional or physician ever told you that you have Body Dysmorphic Disorder (BDD)” and “Has a mental health professional or physician ever told you that you have Muscle Dysmorphia?”

**Muscle dysmorphic disorder inventory (MDDI)**

The MDDI is a 13-item measure that assesses symptoms of muscle dysmorphia [20]. Respondents rate statements on a 1 (never) to 5 (always) scale. The MDDI includes a total score and three subscale scores: Drive for Size (DFS, 5 items, range 5–25), Appearance Intolerance (AI, 4 items, range 4–20), and Functional Impairment (FI, 4 items, range 4–20). The MDDI has demonstrated strong psychometric properties among college-aged men [20], and the factor structure (as well as invariance), internal consistency, reliability, and convergent validity has been supported in cisgender gay men and lesbian women [29, 30]. For cisgender women in this study, item five (“I think my chest is too small”) was modified to specify “chest (muscle)”, so as to not confuse “chest” with breast size [30]. In cisgender gay men, Cronbach’s alpha was 0.77 for the total score, 0.85 for DFS, 0.84 for AI, and 0.84 for FI. In cisgender bisexual plus men, Cronbach’s alpha was 0.69 for the total score, 0.87 for DFS, 0.82 for AI, and 0.78 for FI. In cisgender lesbian women, Cronbach’s alpha was 0.72 for the total score, 0.76 for DFS, 0.81 for AI, and 0.85 for FI. In cisgender bisexual plus women, Cronbach’s alpha was 0.67 for the total score, 0.74 for DFS, 0.80 for AI, and 0.81 for FI.

**Data analysis**

Results are presented in terms of percentiles (standard deviation), median (interquartile range [IQR]), and range. In addition, linear regression analyses were used for group comparisons by sexual orientation within genders (cisgender gay men 0, cisgender bisexual plus men 1; cisgender lesbian women 0, cisgender bisexual plus women 1). Given non-normal distributions of the MDDI total score and the DFS and FI subscale scores, these variables were log transformed. Models included MDDI score as the dependent variable and sexual orientation as the independent variable, separately among cisgender men and cisgender women. Adjusted models included age, race, ethnicity, education, and BMI. Two-tailed tests with an adjusted p-value (Bonferroni) were set at 0.0125 for statistical significance.

The R statistical environment (RStudio, version 3.6.2) was used to calculate norms, and Stata (StataCorp, version 15.1) was used to conduct regression analyses. For missing values (cisgender gay men: 0.06%; cisgender bisexual plus men: 0.04%; cisgender lesbian women: 0.08%; cisgender bisexual plus women: 0.06%), the mechanism of missing data was examined using the nonparametric test of homoscedasticity from the MissMech package.
given that in all cases missing mechanisms were consistent with missing completely at random \((ps > 0.05)\), data imputation was performed using multivariate imputation by chained equations through the \textit{mice} package [32].

\textbf{Results}

\textbf{Cisgender gay men}

Among the 1090 participants who identified as cisgender gay men, the mean age was 42.1 \((SD = 15.1, \text{range 18–82})\) years, and the mean BMI was 27.2 \((SD = 6.3)\) kg/m^2 (Table 1). Of the total subsample of cisgender gay men, 85.1% identified as White, 3.2% as Asian or Pacific Islander, 1.9% as Black, 0.7% as Native American, 4.8% as multiracial, and 4.3% as another race. In addition, 7.6% of the participants identified as Hispanic/Latino/a. Among cisgender gay men, 73.3% had a college degree or higher. Overall, 2.0% of participants reported having ever been told by a healthcare provider that they had BDD, and none reported having been told that they had MD. Norms for the MDDI among cisgender gay men are presented in Table 2.

\textbf{Cisgender bisexual plus men}

Among the 100 participants who identified as cisgender bisexual plus men, the mean age was 38.0 \((SD = 12.8, \text{range 20–76})\) years, and the mean BMI was 28.1 \((SD = 7.1)\) kg/m^2 (Table 1). Among cisgender bisexual plus men, 83.5% identified as White, 7.7% as Asian or Pacific Islander, 2.2% as Black, 1.1% as multiracial, and 5.5% as another race. In addition, 3.0% of the participants identified as Hispanic/Latino/a. Among cisgender bisexual plus men, 75.0% had a college degree or higher. Overall, 2.0% of participants reported having ever been told by a healthcare provider that they had BDD, and none reported having been told that they had MD. Norms for the MDDI among cisgender bisexual plus men are presented in Table 2.

\textbf{Comparisons between cisgender gay men and cisgender bisexual plus men}

In unadjusted linear regression analyses, no significant differences in the MDDI total score \((B = -0.03, 95\% CI -0.09-0.03, p = 0.358)\) or the subscales \((DFS [B = -0.09, 95\% CI -0.18-0.01, p = 0.066], AI [B = -0.35, 95\% CI -1.25-0.55, p = 0.442], \text{and FI [B = 0.06, 95\% CI -0.02-0.14, p = 0.165]})\) were observed for cisgender bisexual plus men compared to cisgender gay men.

In linear regression analyses adjusted for sociodemographics, no significant differences in the MDDI total score \((B = -0.05, 95\% CI -0.10-0.01, p = 0.112)\) or the subscales \((DFS [B = -0.09, 95\% CI -0.17-0.00, p = 0.041], AI [B = -0.80, 95\% CI -1.60-0.01, p = 0.046], \text{and FI [B = 0.05, 95\% CI -0.03-0.14, p = 0.206]})\) were observed for cisgender bisexual plus men compared to cisgender gay men.

\textbf{Cisgender lesbian women}

Among the 563 participants who identified as cisgender lesbian women, the mean age was 38.0 \((SD = 14.3, \text{range 18–77})\) years, and the mean BMI was 29.1 \((SD = 8.1)\) kg/m^2 (Table 1). Among cisgender lesbian women, 85.4% identified as White, 1.6% as Black, 1.3% as Asian or Pacific Islander, 0.5% as Native American, 4.4% as multiracial, and 6.9% as another race. In addition, 6.0% of the participants identified as Hispanic/Latino/a. Among cisgender lesbian women, 73.8% had a college degree or higher. Overall, 2.0% of participants reported having ever been told by a healthcare provider that they had BDD, and none reported having been told that they had MD. Norms for the MDDI among cisgender lesbian women are presented in Table 2.

\begin{table}[h]
\centering
\begin{tabular}{|l|c|c|c|c|}
\hline
& Total & Cisgender gay men & Cisgender bisexual plus men & Cisgender lesbian women & Cisgender bisexual women \\
\hline
N & 2260 & 1090 & 100 & 563 & 507 \\
\hline
Sociodemographic characteristics & Mean ± SD / % & Mean ± SD / % & Mean ± SD / % & Mean ± SD / % & Mean ± SD / % \\
Age, years & 38.6 ± 14.3 & 42.1 ± 15.1 & 38.0 ± 12.8 & 38.0 ± 14.3 & 31.9 ± 9.6 \\
Race & & & & & \\
White & 85.2% & 85.1% & 83.5% & 85.4% & 85.3% \\
Asian/Pacific Islander & 3.0% & 3.2% & 7.7% & 1.6% & 3.1% \\
Black/African American & 2.0% & 1.9% & 2.2% & 1.3% & 2.9% \\
Native American & 0.5% & 0.7% & 0.0% & 0.5% & 0.2% \\
Multiracial/Other & 3.9% & 4.8% & 1.1% & 4.4% & 1.9% \\
Another Race & 5.5% & 4.3% & 5.5% & 6.9% & 6.5% \\
Ethnicity: Hispanic/Latino/a & 6.6% & 7.6% & 3.0% & 6.0% & 5.9% \\
Educational attainment & & & & & \\
College degree or higher & 69.4% & 73.3% & 75.0% & 56.5% & 74.4% \\
Body mass index (BMI), kg/m^2 & 28.1 ± 7.4 & 27.2 ± 6.5 & 28.1 ± 7.1 & 29.1 ± 8.1 & 29.0 ± 8.4 \\
\hline
\end{tabular}
\caption{Sociodemographic characteristics of cisgender sexual minority men and women from The PRIDE Study}
\end{table}
higher. Overall, 2.5% of the participants reported having ever been told by a healthcare provider that they had BDD, and none reported having been told that they had MD. Norms for the MDDI among cisgender lesbian women are presented in Table 3.

Cisgender bisexual plus women
Among the 507 participants who identified as cisgender bisexual plus women, the mean age was 31.9 (SD = 9.6, range 18–71) years and the mean BMI was 29.0 (SD = 8.4) kg/m² (Table 1). Among cisgender bisexual plus women, 85.3% identified as White, 3.1% as Asian or Pacific Islander, 2.9% as Black, 0.2% as Native American, 1.9% as multiracial, and 6.5% as another race. In addition, 5.9% of the participants identified themselves as Hispanic/Latino/a. Among cisgender bisexual plus women, 74.4% had a college degree or higher. Overall, 3.0% of the participants reported having ever been told by a healthcare provider that they had BDD and none reported having been told that they had MD. Norms for the MDDI among cisgender bisexual plus women are presented in Table 3.

Comparisons between cisgender lesbian women and cisgender bisexual plus women
In unadjusted linear regression analyses, no significant differences in the MDDI total score (B = 0.02, 95% CI -0.01-0.05, p = 0.230) or the subscales (DFS [B = 0.00, 95% CI -0.03-0.04, p = 0.855], AI [B = 0.27, 95% CI -0.23-0.77, p = 0.292], and FI [B = 0.01, 95% CI -0.04-0.06, p = 0.580]) were observed for cisgender bisexual plus women compared to cisgender lesbian women.

In linear regression analyses adjusted for sociodemographics, no significant differences in the MDDI total score (B = 0.00, 95% CI -0.03-0.03, p = 0.778) or the subscales (DFS [B = -0.02, 95% CI -0.05-0.02, p = 0.398], AI

---

### Table 2

Means, standard deviations, medians, interquartile ranges, and percentile ranks for the Muscle Dysmorphic Disorder Inventory (MDDI) total and subscale scores among cisgender gay men (N = 1090) and cisgender bisexual plus men (N = 100) from The PRIDE Study

| Cisgender gay men (N = 1090) | Cisgender bisexual plus men (N = 100) |
|-----------------------------|---------------------------------------|
| MDDI DFS | MDDI AI | MDDI FI | MDDI Total | MDDI DFS | MDDI AI | MDDI FI | MDDI Total |
| M (SD) | 9.9 (4.6) | 11.5 (4.3) | 6.1 (3.0) | 27.4 (7.7) | 9.0 (4.2) | 11.1 (4.1) | 6.4 (2.8) | 26.4 (6.4) |
| Mdn (IQR) | 9 (20) | 11 (16) | 5 (16) | 27 (50) | 8 (17) | 11 (16) | 5 (12) | 26 (29) |
| Range | 5–25 | 4–20 | 4–20 | 13–63 | 5–22 | 4–20 | 4–16 | 13–42 |

| Percentile rank | Cisgender gay men | Cisgender bisexual plus men |
|-----------------|------------------|-----------------------------|
| 5               | 5.0              | 5.0                         |
| 10              | 6.0              | 6.0                         |
| 15              | 6.0              | 6.0                         |
| 20              | 7.0              | 7.0                         |
| 25              | 8.0              | 8.0                         |
| 30              | 9.0              | 9.0                         |
| 35              | 10.0             | 10.0                        |
| 40              | 11.0             | 11.0                        |
| 45              | 12.0             | 12.0                        |
| 50              | 13.0             | 13.0                        |
| 55              | 14.0             | 14.0                        |
| 60              | 15.0             | 15.0                        |
| 65              | 16.0             | 16.0                        |
| 70              | 17.0             | 17.0                        |
| 75              | 18.0             | 18.0                        |
| 80              | 19.0             | 19.0                        |
| 85              | 20.0             | 20.0                        |
| 90              | 21.0             | 21.0                        |
| 95              | 22.0             | 22.0                        |
| 99              | 23.0             | 23.0                        |

MDDI: Muscle Dysmorphic Disorder Inventory, MDDI DFS: Drive for Size subscale, MDDI AI: MDDI: Appearance Intolerance subscale, MDDI FI: MDDI: Functional Impairment subscale, M: Mean, SD: Standard deviation, Mdn: Median, IQR: Interquartile range

---

Nagata et al. BMC Psychiatry (2021) 21:297
Table 3 Means, standard deviations, medians, interquartile ranges, and percentile ranks for the Muscle Dysmorphic Disorder Inventory (MDDI) total and subscale scores among cisgender lesbian women (N = 563) and cisgender bisexual plus women (N = 507) from The PRIDE Study

|                          | Cisgender lesbian women (N = 563) | Cisgender bisexual plus women (N = 507) |
|--------------------------|-----------------------------------|----------------------------------------|
|                          | MDDI DFS  | MDDI AI  | MDDI FI  | MDDI Total | MDDI DFS  | MDDI AI  | MDDI FI  | MDDI Total |
| M (SD)                   | 6.4 (2.5) | 11.9 (4.1) | 6.1 (3.0) | 24.3 (6.1) | 6.4 (2.4) | 12.2 (3.9) | 6.1 (2.9) | 24.6 (5.5) |
| Mdn (IQR)                | 5 (16)    | 12 (16)   | 4 (16)    | 24 (41)    | 5 (16)    | 12 (16)   | 5 (16)    | 24 (31)    |
| Range                    | 5–21      | 4–20      | 4–20      | 13–54      | 5–21      | 4–20      | 4–20      | 13–44      |

Percentile rank
- 5: 5.0, 5.0, 4.0, 15.2
- 10: 5.0, 6.0, 4.0, 16.3
- 15: 5.0, 7.0, 4.0, 18.0
- 20: 5.0, 8.0, 4.0, 19.0
- 25: 5.0, 9.0, 4.0, 20.0
- 30: 5.0, 10.0, 4.0, 21.0
- 35: 5.0, 10.0, 4.0, 22.0
- 40: 5.0, 11.0, 4.0, 23.0
- 45: 5.0, 11.0, 4.0, 23.0
- 50: 5.0, 12.0, 4.0, 24.0
- 55: 5.0, 13.0, 5.0, 24.0
- 60: 5.0, 13.0, 5.0, 25.8
- 65: 6.0, 14.0, 6.0, 26.0
- 70: 6.0, 15.0, 7.0, 27.0
- 75: 7.0, 15.0, 7.0, 28.0
- 80: 7.0, 16.0, 8.0, 29.0
- 85: 8.0, 16.0, 9.0, 30.0
- 90: 10.0, 17.0, 10.0, 32.0
- 95: 12.0, 18.0, 13.0, 35.0
- 99: 16.0, 20.0, 16.4, 41.4

[B = 0.19, 95% CI -0.28-0.65, p = 0.432], and FI [B = 0.03, 95% CI -0.05-0.05, p = 0.894]) were observed for cisgender bisexual plus women compared to cisgender lesbian women.

**Discussion**

Sexual minority populations have been mostly neglected in the MD literature, despite evidence of greater levels of body dissatisfaction and drive for muscularity among individuals with sexual minority identities [13–16]. Further, most prior validation studies of the MDDI did not assess and/or report sexual orientation data for the samples [5, 9, 23, 24, 26, 33–35]. In this study, we provide the first norms for the MDDI in community samples of cisgender sexual minority men and women. Specifically, we examined the MDDI in cisgender gay men, cisgender bisexual plus men, cisgender lesbian women, and cisgender bisexual plus women. Notably, we did not find significant differences in MDDI scores between cisgender gay men compared to cisgender bisexual plus men, or between cisgender lesbian women compared to cisgender bisexual plus women in unadjusted or adjusted comparisons. This study contributes to the literature on MD among sexual minorities, providing norms for the MDDI and informing a broader understanding of the nature and degree of MD symptoms in cisgender sexual minority men and women from the broad U.S. community.

Compared to the initial MDDI validation study in a selected sample of heterosexual male weightlifters (presumably cisgender men) [20], our community sample of cisgender sexual minority men reported qualitatively higher MDDI total scores (26.4–27.4 vs 18.8), DFS subscale scores (9.0–9.9 vs. 7.5), and AI subscale scores (11.1–11.5 vs 6.12) but similar FI subscale scores (6.1–6.4 vs. 6.4). This is noteworthy, as we would expect even greater differences in the scores found here versus those from a general community sample of heterosexual men.
The unique factors that may contribute to the development, maintenance, or exacerbation of MD symptoms among sexual minorities require further research. Minority stress theory, which suggests that stigma, prejudice, and discrimination experienced by sexual minorities may lead to health disparities [36], may be an important consideration with regard to the experience of MD symptoms in sexual minority individuals. For example, individuals experiencing minority stress may experience psychological (e.g., depressive or anxious symptoms, low self-esteem) or behavioral disturbances (e.g., pathological exercise, eating pathology) that could contribute to elevated risk for muscularity-oriented psychopathology, including MD [37–39]. Further, sexual minority people may experience intra-minority stress, which represents unique status-based competitive and appearance pressures emerging from within sexual minority communities [40, 41]. Bisexual plus people may also experience biphobia, which represents the additional stressors from people with monosexual orientations, including gay, lesbian, or heterosexual people [42]. Despite the additional stressors experienced by bisexual plus people, we did not see significant differences in the MDDI between cisgender bisexual plus men and cisgender gay men, or between cisgender bisexual plus women and cisgender lesbian women.

**Implications and conclusions**

This study has several potential clinical and research implications. We report for the first time MDDI norms among cisgender gay men, cisgender bisexual plus men, cisgender lesbian women, and cisgender bisexual plus women. Given that health differences and disparities by sexual orientation are increasingly recognized, establishing descriptive data about MD may enable clinicians and researchers to interpret MDDI scores among these understudied populations. Clinicians should be aware that cisgender sexual minority men and women may experience MD symptoms and should consider assessing for these symptoms and related behaviors when appropriate. In particular, sexual minority community centers and organizations may consider raising awareness and providing support for MD. Future research will be needed to examine the MDDI in clinical samples of sexual minorities diagnosed with MD, and investigate how sociodemographic factors such as race/ethnicity, age, and socioeconomic status may influence the nature and degree of MD symptoms among cisgender sexual minority men and women. Research of this kind will help inform the development of targeted interventions to address MD symptoms in these underserved populations.

**Strengths/limitations**

Strengths of this investigation include the focus on understudied populations in the MD literature, the large sample sizes across most groups, and the focus on a widely used and well-validated measure of MD symptoms. However, certain limitations also should be noted. Overall, the samples were highly educated, predominantly White, and recruited online, which may limit generalizability. The sample of bisexual plus men was also notably smaller than the other samples. Further, we defined bisexual plus as people who identified as bisexual, pansexual, and/or polysexual, which may obscure potential differences across these groups. Given that the construct of MD was originally conceptualized predominantly in reference to cisgender men, and in light of the different sociocultural body ideals for men and women, the MDDI may be less applicable to cisgender women; however, we made a slight adaptation for cisgender women to specify “chest (muscle)” so as to not confuse “chest” with breast size [30]. Nevertheless, better understanding the construct and measurement of MD in cisgender women versus cisgender men will require further research. Finally, although gender minorities are also understudied in the MD literature, this study focused on cisgender sexual minorities; investigating the MDDI in gender minorities will therefore be an important area for future research.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12888-021-03302-2.

**Acknowledgments**

We thank Samuel Benabou and Kelsey Wu for editorial assistance. The PRIDE Study is a community-engaged research project that serves and is made possible by LGBTQ+ community involvement at multiple points in the research process, including the dissemination of findings. We acknowledge the courage and dedication of The PRIDE Study participants for sharing their stories, the careful attention of PRIDEnet Participant Advisory Committee (PAC) members for reviewing and improving every study application, and the enthusiastic engagement of PRIDEnet Ambassadors and Community Partners for bringing thoughtful perspectives as well as promoting enrollment and disseminating findings. For more information, please visit https://pridenet.org/pridenet.

**Authors’ contributions**

J.M.N.: Conceptualization, Formal analysis, Methodology, Writing - original draft, Writing - review & editing. E.I.C.: Formal analysis, Methodology, Writing - original draft, Writing - review & editing. C.J.C.: Writing - original draft, Writing - review & editing. J.M.L.: Writing - original draft, Writing - review & editing. T.A.B.: Writing - original draft, Writing - review & editing. S.B.M.: Conceptualization, Writing - review & editing. A.F.: Conceptualization, Methodology, Writing - review & editing. M.R.C.: Conceptualization, Methodology, Writing - review & editing. M.E.L.: Conceptualization, Methodology, Writing - review & editing. M.R.L.: Conceptualization, Funding, Methodology, Writing, – review & editing. J.O.M.: Conceptualization, Funding, Methodology, Writing - review & editing. E.J.C.: Formal analysis, Methodology, Writing - review & editing.
Received: 28 January 2021 Accepted: 24 May 2021
Published online: 08 June 2021

Methodology, Writing - review & editing. The authors read and approved the final manuscript.

Funding
Supported by the Pediatric Scientist Development Program supported by the American Academy of Pediatrics and American Pediatric Society to JN. MC was supported by a Clinical Research Training Fellowship from the American Academy of Neurology and the Tourette Association of America. SBM was supported by the National Institutes of Health (K23 MH115184). JOM was partially supported by grant K12DK111028 from the National Institute of Diabetes, Digestive, and Kidney Disorders. AF was supported by the National Institute on Drug Abuse (K23DA039800). Research reported in this article was partially funded through a Patient-Centered Outcomes Research Institute (PCORI, www.pcori.org) Award (PPRN-1501-26848) to MRL. The statements in this article are solely the responsibility of the authors and do not necessarily represent the views of PCORI, its Board of Governors or Methodology Committee, the National Institutes of Health, the Uniformed Services University, or the Department of Defense.

Availability of data and materials
Data from The PRIDE Study may be accessed through an Ancillary Study application (details at pridestudy.org/collaborate).

Declarations

Ethics approval and consent to participate
The University of California, San Francisco (#16–21213) and Stanford University (#48707) Institutional Review Boards approved this study. Written informed consent was obtained from all participants. All study procedures and methods were carried out in accordance with relevant guidelines and regulations.

Consent for publication
Not applicable.

Competing interests
Dr. Juno Obedin-Maliver has consulted for Sage Therapeutics ($5/2017) in a one-day advisory board, Ibis Reproductive Health (a non-for-profit research group; 3/2017–5/2018, 2020-present), Hims Inc. (2019 - present), and Folkx, Inc. (2020 – present). Dr. Lunn has consulted for Hims Inc. (2019 - present) and Folkx, Inc. (2020). None of these roles present a conflict of interest with this work as described here. The other authors have no conflicts of interest to report.

Author details
1Department of Pediatrics, University of California, San Francisco, Box 0110, 550 16th Street, 4th Floor, San Francisco, CA 94158, USA. 2Eating Behavior Research Center, School of Psychology, Universidad Adolfo Ibáñez, Santiago, Chile. 3Research Department, Comenzar de Nuevo Treatment Center, Monterrey, Mexico. 4Military Cardiovascular Outcomes Research Program (MiCOR), Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. 5The Metis Foundation, San Antonio, TX, USA. 6Department of Psychiatry, University of California, San Diego, San Diego, CA, USA. 7San Diego State University Research Foundation, San Diego, CA, USA. 8Department of Psychiatry and Behavioral Sciences, University of Southern California, Los Angeles, CA, USA. 9Department of Community Health Systems, University of California, San Francisco, San Francisco, CA, USA. 10Alliance Health Project, Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA, USA. 11The PRIDE Study/PRIDEnet, Stanford University School of Medicine, Stanford, CA, USA. 12Department of Psychology, San Jose State University, San Jose, CA, USA. 13Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA, USA. 14Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA. 15Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.

References

1. American Psychiatric Association. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders Fifth Edition. 2013.
2. Pope HG, Gruber AJ, Choi P, Olvidaria R, Phillips KA. Muscle dysmorphia: an underrecognized form of body dysmorphic disorder. Psychosomatics. 1997;38(6):548–57. https://doi.org/10.1016/S0033-3182(97)71400-2.
3. Hildebrandt T, Schlundt D, Langenbucher J, Chung T. Presence of muscle dysmophoria symptomology among male weightlifters. Compr Psychiatry. 2006;47(2):127–35. https://doi.org/10.1016/j.comppsych.2005.06.001.
4. Pope CG, Pope HG, Menard W, Fawcett C, Olvidaria R, Phillips KA. Clinical features of muscle dysmophoria among males with body dysmorphic disorder. Body Image. 2005;2(4):395–400. https://doi.org/10.1016/j.bodyim.2005.09.001.
5. Zeeck A, Welter V, Alatas H, Hildebrandt T, Lahmann C, Hartmann A. Muscle dysmorphic disorder inventory (MDDII): validation of a German version with a focus on gender. PLoS One. 2018;13(11):e0207535. https://doi.org/10.1371/journal.pone.0207535.
6. Cafri G, Olvidaria R, Thompson JK. Symptom characteristics and psychiatric comorbidity among males with muscle dysmophoria. Compr Psychiatry. 2008;49(4):374–9. https://doi.org/10.1016/j.comppsych.2008.01.003.
7. Longobardi C, Primo LE, Fabris MA, Settanni M. Muscle dysmophia and psychopathology: findings from an Italian sample of male bodybuilders. Psychiatry Res. 2017;256:231–6. https://doi.org/10.1016/j.psychres.2017.06.065.
8. Pope HG, Katz DL, Hudson JI. Anorexia nervosa and “reverse anorexia” among 108 male bodybuilders. Compr Psychiatry. 1993;34(6):406–9. https://doi.org/10.1016/0010-440X(93)90066-D.
9. Compte EJ, Nagata JM, Sepúlveda AR, Rivas A, Sibar LS, Menga S, et al. Assessment and validation of a Spanish version of the muscle dysmorphic disorder inventory in Argentinian men who exercise: Investigatorio de Dismorfia muscular. Body Image. 2019;21:23–4. https://doi.org/10.1016/j.bodyim.2019.08.002.
10. Tod D, Edwards C, Cranswick I. Muscle dysmophia: current insights. Psychol Res Behav Manag. 2016;9:179–88. https://doi.org/10.2147/PBRM.S97404.
11. Murray SB, Nagata JM, Griffiths S, Calzo JP, Brown TA, Mitchison D, et al. The enigma of male eating disorders: a critical review and synthesis. Clin Psychol Rev. 2017;57:1–11. https://doi.org/10.1016/j.cpr.2017.08.001.
12. dos Santos Filho CA, Triczko PP, Stefano SC, Touyz SW, Claudino AM. Systematic review of the diagnostic category muscle dysmorphia. Aust N Z J Psychiatry. 2016;50(4):322–33. https://doi.org/10.1177/0004864416614106.
13. Frederick DA, Essayli JH. Male body image: The roles of sexual orientation and body mass index across five national U.S. studies. Psychol Men Masculinity. 2016;17:191–203. https://doi.org/10.1007/s11199-016-9400-1.
14. Kaminski PL, Chapman BP, Haynes SD, Own L. Body image, eating behaviors, and attitudes toward exercise among gay and straight men. Eat Behav. 2005;6(3):179–87. https://doi.org/10.1016/j.eatbeh.2004.11.003.
15. Yelland C, Tiggemann M. Muscularity and the gay ideal: body dissatisfaction and disordered eating in homosexual men. Eat Behav. 2003;4(2):107–16. https://doi.org/10.1016/S1471-0153(03)00014-X.
16. Yean C, Benau EM, Dakanalis A, Hornes JM, Perone J, Timko CA. The relationship of sex and sexual orientation to self-esteem, body shape satisfaction, and eating disorder symptomatology. Front Psychol. 2013;4:887.
17. Martins Y, Tiggemann M, Churchett L. The shape of things to come: gay men’s satisfaction with specific body parts. Psychol Men Masculinity. 2009;9(4):248–58. https://doi.org/10.1007/s11199-009-9029-x.
18. Boroughs MS, Kawczyk R, Thompson JK. Body dysmorphic disorder among diverse racial/ethnic and sexual orientation groups: prevalence estimates and associated factors. Sex Roles. 2010;63(9–10):725–37. https://doi.org/10.1007/s11199-010-9831-1.
19. Oshana A, Klimpek P, Blashill AJ. Minority stress and body dysmorphic disorder symptoms among sexual minority adolescents and adult men. Body Image. 2020;34:167–74. https://doi.org/10.1016/j.bodyim.2020.06.001.
20. Hildebrandt T, Langenbucher J, Schlundt DG. Muscle surpassing anxiety among men: development of attitudinal and perceptual measures. Body Image. 2004;1(2):169–81. https://doi.org/10.1016/j.bodyim.2004.01.001.
21. Mitchell L, Murray SB, Coblentz S, Hackett D, Gifford J, Capling L, et al. Muscle dysmorphia symptomatology and associated psychological features in bodybuilders and non-bodybuilder resistance trainers: a systematic review
and meta-analysis. Sports Med. 2017;47(2):233–59. https://doi.org/10.1007/s40279-016-0564-3.

22. Galiana-Linares L, Badenes-Rivera L, Fuentes-Durán MC. In: Scinfoper, editor. Validación de la versión española del Inventario del Trastorno por Dismorfia Muscular en una muestra de estudiantes universitarios: Atención a las necesidades comunitarias para la salud, 2017. p. 41–5.

23. Gomes WMOM, Compte EJ, Almeida M, Campos PF, ACC Q, Pereira LF, et al. Psychometric Properties of the Muscle Dysmorphic Disorder Inventory Among Physically Active Brazilian College Men. Psychol Men Masculinity. 2020;21(4):62–31. https://doi.org/10.1037/men0000307.

24. Sandgren SS, Giske R, Shafawi SA. Muscle dysmophia in norwegian gym-going men: an initial investigation. Kinesiology. 2019;51(1):12–21. https://doi.org/10.26992/k.51.1.3.

25. Santamecchi E, Dettore D. Muscle dysmorphism in different degrees of bodybuilding activities: validation of the Italian version of muscle dysmorphic disorder inventory and bodybuilder image grid. Body Image. 2012;9(3):396–403. https://doi.org/10.1016/j.bodyim.2012.03.006.

26. Sepúlveda AR, Rica R, Moreno A, Román FJ, Compte EJ. Assessing the male body image. Spanish validation of two instruments. Psychiatry Res. 2019; 272(December 2018):483–50.

27. Lunn MR, Capriotti MR, Flentje A, Bibbins-Domingo K, Pletcher MJ, Triano DJ, et al. Using mobile technology to engage sexual and gender minorities in clinical research. PLoS One. 2019;14(5):e0216282. https://doi.org/10.1371/journal.pone.0216282.

28. Lunn MR, Lubensky M, Hunt C, Flentje A, Capriotti MR, Sooskaman C, et al. A digital health research platform for community engagement, recruitment, and retention of sexual and gender minority adults in a national longitudinal cohort study—The PRIDE Study. J Am Med Inform Assoc. 2019; 26(8-9):737–48. https://doi.org/10.1093/jamia/ocz082.

29. Strübel J, Petrie TA. Appearance and performance enhancing drug usage and psychological well-being in gay and heterosexual men. Psychol Sex. 2019;10:132–48.

30. Compte EJ, Cattle CJ, Lavender JM, Murray SB, Brown TA, Capriotti MR, et al. Muscle dysmorphic disorder inventory and bodybuilder image grid. Psychiatry Res. 2019;272(December 2018):190-197. https://doi.org/10.1016/j.biopsych.2019.08.010.

31. https://doi.org/10.1037/men0000307.

32. https://doi.org/10.1037/pspp0000282.

33. https://doi.org/10.1007/s40279-016-0564-3.

34. Nagata et al. BMC Psychiatry (2021) 21:297 Page 9 of 9

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.